Partial operating KPIs
This page has 3 company-specific operating KPI charts. A sourced floor is 4. Sector membership does not count.
Boehringer Ingelheim Survodutide: SYNCHRONIZE + LIVERAGE Phase 3 Design
| Trial / Phase | Indication / Design | Primary Endpoint + Readout Window |
|---|---|---|
| Phase 1 SAD/MAD | Healthy volunteers + obesity cohort | 2017-2019 readouts; demonstrated dose-related pharmacokinetics + initial weight reduction; supported Phase 2 advancement |
| Phase 2 obesity (46 weeks) | Obesity Phase 2b | Mar 2023 topline: up to ~18.7% mean weight loss at 46 weeks at the 4.8mg weekly high dose vs ~2.0% placebo; GI tolerability comparable to other dual incretins; supports Phase 3 advancement |
| Phase 2 MASH biopsy (NEJM, 48 weeks) | MASH Phase 2b; 293 patients, fibrosis F1-F3 | NEJM June 7, 2024: dose-related improvement in MASH without worsening of fibrosis across 2.4/4.8/6.0mg, statistically superior to placebo (up to ~83% at the 6.0mg dose vs ~18% placebo); fibrosis improvement up to ~64.5% as a key secondary; supported the LIVERAGE Phase 3 program |
| SYNCHRONIZE-1 (Phase 3 obesity, registrational) | Obesity without T2D; ~725 patients | Primary endpoint weight loss at 76 weeks; April 2026 topline: up to 16.6% mean weight loss vs 3.2% placebo at 76 weeks; supports EU + FDA filing pathway |
| SYNCHRONIZE-2 (Phase 3 obesity in type 2 diabetes) | Obesity/overweight with type 2 diabetes | Phase 3 registrational trial; weight-loss primary endpoint in people with obesity and T2D; parallel pathway alongside SYNCHRONIZE-1 |
| SYNCHRONIZE-CVOT (cardiovascular outcomes) | Phase 3 cardiovascular outcomes | Long-duration cardiovascular outcomes trial supporting a CV-risk-reduction labeling claim; supports premium positioning vs semaglutide + tirzepatide; long-duration readout |
| LIVERAGE (Phase 3 MASH, F2-F3) | F2-F3 MASH; histology endpoints | Phase 3 MASH trial in fibrosis stages F2-F3; MASH resolution + fibrosis improvement at 52 weeks, with long-term outcomes follow-on; competing with Rezdiffra (approved March 2024), semaglutide (MASH approval August 2025), and efruxifermin (Novo/Akero) |
| LIVERAGE-Cirrhosis (Phase 3 MASH, F4) | F4 compensated cirrhosis | Phase 3 MASH trial in compensated cirrhosis (fibrosis stage F4); evaluates fibrosis and long-term clinical outcomes in the highest-fibrosis subset |
| Zealand Pharma partnership economics | Royalty + milestone obligations | Boehringer pays Zealand royalties on net commercial sales plus development, regulatory, and commercial-launch milestones per the 2011 collaboration; the royalty rate is undisclosed |
| Boehringer obesity-franchise allocation | R&D + capital allocation | Boehringer Ingelheim does not disclose Human Pharma R&D at the franchise level; survodutide is its single named obesity + MASH asset. It supports its positioning as the only top-10 Big Pharma without a public listing competing in the GLP-1 space |
| Editorial. Why survodutide matters | Strategic context | Survodutide is among the most-advanced glucagon/GLP-1 dual agonists globally and the only Big Pharma asset in this mechanism class. Its Phase 2 obesity result (~18.7% at 46 weeks) and the SYNCHRONIZE-1 Phase 3 result (16.6% at 76 weeks) position Boehringer as a credible #3 Big Pharma incretin franchise behind LLY + NVO. The MASH indication is strategically important: survodutide could give Boehringer both obesity + MASH labels for a single asset |
Boehringer Ingelheim Cumulative Payments to Zealand Pharma (Survodutide Partnership)

Boehringer Ingelheim in GLP-1
KPI data tables
Boehringer Ingelheim operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Human Pharma R&D (other therapy areas) | Obesity + cardiometabolic (survodutide, est.) | Animal Health R&D |
|---|---|---|---|
| 2024 | 5,350 | 350 | 500 |
| 2023 | 4,950 | 250 | 600 |
| 2022 | 4,400 | 180 | 420 |
| 2021 | 3,500 | 130 | 450 |
| 2020 | 3,150 | 90 | 460 |
Source: Boehringer Ingelheim annual reports (boehringer-ingelheim.com; published annually for the prior calendar year); Human Pharma + Animal Health R&D split disclosed in the financial review. Reported group/Human-Pharma R&D: 2024 ~EUR 6.2B group / ~EUR 5.7B Human Pharma; 2023 ~EUR 5.8B / ~EUR 5.2B; 2022 ~EUR 5.0B group. The Human-Pharma + Animal-Health totals match reported figures; the obesity/cardiometabolic sub-allocation is estimate-driven because BI does not disclose therapy-area-level R&D budgets.
| Period | Cumulative BI payments to Zealand (EUR millions, estimated) |
|---|---|
| 2024 | 150 |
| 2023 | 140 |
| 2022 | 110 |
| 2020 | 95 |
| 2015 | 55 |
| 2011 | 41 |
Source: Zealand Pharma annual + interim reports (counterparty disclosure of payments received from the Boehringer partnership); original 2011 partnership announcement (lead candidate ZP2929); disclosed milestone receipts (~EUR 20M in 2020, ~EUR 30M in 2023). The cumulative curve is estimate-driven and anchored to these disclosed milestones (Zealand aggregates partner revenue rather than itemizing a BI-specific cumulative figure), so intermediate-year values are approximate.